A Post-licensure Surveillance Program for the Safety of GARDASIL in a Managed Care Organization Setting.

Trial Profile

A Post-licensure Surveillance Program for the Safety of GARDASIL in a Managed Care Organization Setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Oct 2012 Results have been published in Archives of Pediatrics and Adolescent Medicine according to a Kaiser Permanente media release. Results were also summarised in the media release.
    • 25 Jan 2012 Results were published in the Journal of Internal Medicine, according to a Kaiser Permanente media release.
    • 23 Nov 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top